An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)

2024-516781-10-00 Human pharmacology (Phase I) - First administration to humans Ended

Start 16 Sep 2024 · End 23 Dec 2025 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 17
Countries 1
Sites 1

High grade serous ovarian cancer

Key facts

Sponsor
Universitair Medisch Centrum Groningen
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
16 Sep 2024 → 23 Dec 2025
Decision date (initial)
2024-09-16
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516781-10-00
EudraCT number
2020-003600-13
ClinicalTrials.gov
NCT04739527

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

High grade serous ovarian cancer

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitair Medisch Centrum Groningen

Sponsor organisation
Universitair Medisch Centrum Groningen
Address
Hanzeplein 1
City
Groningen
Postcode
9713 GZ
Country
Netherlands

Scientific contact point

Organisation
Universitair Medisch Centrum Groningen
Contact name
H.W. Nijman

Public contact point

Organisation
Universitair Medisch Centrum Groningen
Contact name
H.W. Nijman

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 17 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Universitair Medisch Centrum Groningen
Obstetrics and gynecology, Hanzeplein 1, 9713 GZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-09-16 2025-12-23 2024-09-16

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-19 Netherlands Acceptable with conditions
2024-09-16
2024-09-16
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-17 Netherlands Acceptable
2024-10-30
2024-10-30
3 SUBSTANTIAL MODIFICATION SM-2 2024-11-13 Netherlands Acceptable
2024-11-19
2024-11-19